Antibodies

On Tuesday, Alyssa Vance, a poster on X.com, formerly Twitter, highlighted an opportunity for individuals to participate in a human challenge trial aimed at combating malaria. What Happened: Vance took to Twitter to share information about a human challenge trial where participants can earn $5,400...

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescinded by the U.S. Food And Drug Administration. What Happened: The regulator...

Regeneron Pharmaceutical Inc.’s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail reduced the risk of death by 20% in hospitalized COVID-19 patients who have not mounted their own antibody response, a large-scale study in the U.K. published on Wednesday found. What Happened: Regeneron said...

Eli Lilly and Co (NYSE: LLY)’s antibody treatments have received an emergency use authorization from the United States Food and Drug Administration. What Happened: The federal regulator issued the EUA for the two drugs, bamlanivimab and etesevimab, to be administered together for the...

Biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the signing of a $2.625 billion supply agreement with the U.S. government for its COVID-19 antibody cocktail. What Happened: The U.S. Department of Health and Human Services and the Department of Defense have decided to buy an...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) disclosed Tuesday that its antibody cocktail showed positive results in early-stage trials for hospitalized patients. What Happened: Regeneron’s treatment, a blend of two antibodies — Casirivimab and Imdevimab, was tested in...

The United States Food and Drug Administration has issued an emergency use authorization for Eli Lilly and Company’s (NYSE: LLY) monoclonal antibody treatment bamlanivimab for use against COVID-19 in both adults and children. What Happened: Under the EUA, the treatment can be distributed and...

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) said Wednesday data from late-stage clinical trials is indicative that its antibody cocktail for COVID-19 both reduced viral load and need for medical attention. What Happened: The antibody therapy reduced COVID-19-related medical visits by 57% among...

President Donald Trump touted Regeneron Pharmaceuticals Inc’s (NASDAQ: REGN) antibody cocktail as a "cure" for COVID-19 in a video shared after his return to the Oval Office on Wednesday. What Happened: “I wasn't feeling so hot, and within a very short...

Antibody drugs currently undergoing testing could be a panacea for the COVID-19 pandemic ravaging the world once they get regulatory approval, according to the founder of Microsoft Corporation (NASDAQ: MSFT) Bill Gates. What Happened: The drugs, known as monoclonal antibodies, have shown promising...

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) announced Tuesday that its antibody cocktail drug showed positive effects in non-hospitalized COVID-19 patients. What Happened: Analysis of data from a 275 person study indicates that the REGN-COV2 drug cocktail led to reduced viral load and time...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Monday that a non-peer-reviewed study indicated its antibody drug combination both prevented and treated COVID-19 in animals, as earlier reported by Reuters. What Happened The drugmaker noted a cocktail of two monoclonal antibodies...